Bone marrow M2 is an acute myeloid leukemia type M2, and the duration of treatment will vary depending on the extent of the disease, the individual’s physical fitness, and the sensitivity of the therapeutic drugs. Acute myeloid leukemia type M2 is a myeloid leukemia for which the preferred treatment is systemic chemotherapy, which can be divided into induced remission therapy and post-remission therapy. For those with M2 type, they can be categorized into low-risk, intermediate-risk, and high-risk groups based on the results of chromosomal and genetic tests, and the treatments vary according to the patient’s risk. 1.Induction of remission treatment Commonly used chemotherapy methods are DA regimen, HA regimen, MA regimen and so on. The drugs include cytarabine, hypertriglyceridines, mitoxantrone, zorubicin and so on. 2. After induction of remission, the low-risk and intermediate-risk groups can be maintained with conventional chemotherapy or can be treated with bone marrow transplantation. For the high-risk group, allogeneic hematopoietic stem cell transplantation is preferred after induction of remission. If the patient is in the early stage of the disease, his/her physical condition is better, and he/she is sensitive to chemotherapeutic drugs, it will shorten the course of treatment, but on the contrary, it may lead to an increase in the course of induced remission, and there may also be chemotherapy failure. Acute myeloid leukemia type M2 is treatable and should be treated with chemotherapy as early as possible under the guidance of a doctor after diagnosis.